Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
Zacks.com on MSN17h
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority TagSanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...
The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback